Anti‐CD52 mAb maintenance therapy vs observation: Progression‐free survival
It is very uncertain whether anti‐CD52 mAb maintenance therapy changes progression‐free survival compared with observation (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐CD52 mAb maintenance therapy vs observation Progression‐free survival · people with chronic lymphocytic leukaemia It is very uncertain whether anti‐CD52 mAb maintenance therapy changes progression‐free survival compared with observation (very low certainty). Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane Headline outcomes only | HR 0.55 [0.32, 0.95] | 1 study · 21 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.